Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment

Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment

Summary. Aim: To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes. Materials and Methods: We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Datum:2023
Hauptverfasser: Chekhun, V.F., Borikun, T.V., Bazas, V.М., Andriiv, A.V., Klyusov, O.М., Yalovenko, T.М., Lukianova, N.Yu.
Format: Artikel
Sprache:English
Veröffentlicht: PH Akademperiodyka 2023
Schlagworte:
breast cancer
miRNA
resistance
Online Zugang:https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Experimental Oncology

Institution

Experimental Oncology
id oai:ojs2.ex.aqua-time.com.ua:article-165
record_format ojs
spelling oai:ojs2.ex.aqua-time.com.ua:article-1652023-10-11T16:43:26Z Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment Chekhun, V.F. Borikun, T.V. Bazas, V.М. Andriiv, A.V. Klyusov, O.М. Yalovenko, T.М. Lukianova, N.Yu. breast cancer, miRNA, resistance breast cancer, miRNA, resistance Summary. Aim: To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes. Materials and Methods: We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast cancer patients using real-time polymerase chain reaction. Each case was characterized by TMN criteria using morphological and immunohistochemical analyses. Results: Serum levels of miR-205 and -375 are associated with the response of luminal A tumors and miR-205 and -21 with the response of luminal B tumors to neoadjuvant polychemotherapy in fluorouracil + doxorubicin + cyclophosphamide and doxorubicin + cyclophosphamide regimens. In addition, we found correlation of miR-155, -182, -199a, -375 with 3-year relapse-free survival of patients. Based on the obtained data, we developed innovative prognostic and predictive panels to assess the drug sensitivity of tumors and lower the risk of breast cancer recurrence, which would significantly improve the treatment outcomes and the quality of life of patients. Conclusions: Serum levels of miR-155, -182, -199a, -205, -375 can be used as predictive and prognostic panel for monitoring BC course in Ukrainian population. Summary. Aim: To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes. Materials and Methods: We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast cancer patients using real-time polymerase chain reaction. Each case was characterized by TMN criteria using morphological and immunohistochemical analyses. Results: Serum levels of miR-205 and -375 are associated with the response of luminal A tumors and miR-205 and -21 with the response of luminal B tumors to neoadjuvant polychemotherapy in fluorouracil + doxorubicin + cyclophosphamide and doxorubicin + cyclophosphamide regimens. In addition, we found correlation of miR-155, -182, -199a, -375 with 3-year relapse-free survival of patients. Based on the obtained data, we developed innovative prognostic and predictive panels to assess the drug sensitivity of tumors and lower the risk of breast cancer recurrence, which would significantly improve the treatment outcomes and the quality of life of patients. Conclusions: Serum levels of miR-155, -182, -199a, -205, -375 can be used as predictive and prognostic panel for monitoring BC course in Ukrainian population. PH Akademperiodyka 2023-05-31 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-2 10.32471/exp-oncology.2312-8852.vol-42-no-3.14805 Experimental Oncology; Vol. 42 No. 3 (2020): Experimental Oncology; 162-166 Експериментальна онкологія; Том 42 № 3 (2020): Експериментальна онкологія; 162-166 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-3 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-2/2020-3-2 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/
institution Experimental Oncology
baseUrl_str
datestamp_date 2023-10-11T16:43:26Z
collection OJS
language English
topic breast cancer
miRNA
resistance
spellingShingle breast cancer
miRNA
resistance
Chekhun, V.F.
Borikun, T.V.
Bazas, V.М.
Andriiv, A.V.
Klyusov, O.М.
Yalovenko, T.М.
Lukianova, N.Yu.
Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
topic_facet breast cancer
miRNA
resistance
breast cancer
miRNA
resistance
format Article
author Chekhun, V.F.
Borikun, T.V.
Bazas, V.М.
Andriiv, A.V.
Klyusov, O.М.
Yalovenko, T.М.
Lukianova, N.Yu.
author_facet Chekhun, V.F.
Borikun, T.V.
Bazas, V.М.
Andriiv, A.V.
Klyusov, O.М.
Yalovenko, T.М.
Lukianova, N.Yu.
author_sort Chekhun, V.F.
title Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
title_short Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
title_full Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
title_fullStr Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
title_full_unstemmed Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
title_sort association of circulating mir-21, -205, and -182 with response of luminal breast cancers to neoadjuvant fac and ac treatment
title_alt Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
description Summary. Aim: To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes. Materials and Methods: We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast cancer patients using real-time polymerase chain reaction. Each case was characterized by TMN criteria using morphological and immunohistochemical analyses. Results: Serum levels of miR-205 and -375 are associated with the response of luminal A tumors and miR-205 and -21 with the response of luminal B tumors to neoadjuvant polychemotherapy in fluorouracil + doxorubicin + cyclophosphamide and doxorubicin + cyclophosphamide regimens. In addition, we found correlation of miR-155, -182, -199a, -375 with 3-year relapse-free survival of patients. Based on the obtained data, we developed innovative prognostic and predictive panels to assess the drug sensitivity of tumors and lower the risk of breast cancer recurrence, which would significantly improve the treatment outcomes and the quality of life of patients. Conclusions: Serum levels of miR-155, -182, -199a, -205, -375 can be used as predictive and prognostic panel for monitoring BC course in Ukrainian population.
publisher PH Akademperiodyka
publishDate 2023
url https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-2
work_keys_str_mv AT chekhunvf associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
AT borikuntv associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
AT bazasvm associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
AT andriivav associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
AT klyusovom associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
AT yalovenkotm associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
AT lukianovanyu associationofcirculatingmir21205and182withresponseofluminalbreastcancerstoneoadjuvantfacandactreatment
first_indexed 2025-07-17T12:16:01Z
last_indexed 2025-07-17T12:16:01Z
_version_ 1844164841378414592

Ähnliche Einträge